Skip to Main Content

Dear Readers,

On the day STAT launched 15 months ago, we published a months-long investigation into a failed vitamin business, based on bad science, promoted by Donald Trump.

All along Trump’s march toward the White House, we’ve delivered authoritative, original, and fair-minded coverage of him and his political rivals, both in text and multimedia. Among our many Trump scoops: An exclusive interview with his doctor; the first story that raised questions about his HHS nominee’s conflicts of interest; and a piece exploring the influence of tech billionaire Peter Thiel on the transition team as it vets candidates to run the FDA and NIH.


This morning, we’ve got short bulletins from 13 of our beat reporters explaining what they’ll be watching as Trump’s administration begins. We’re expecting fundamental changes in health and science policy. And we’ll be there at every turn, with insights, analysis, and probing reporting from D.C., Boston, and our reporters around the country.

Two important stories last week underscored our commitment. When Robert F. Kennedy Jr. announced that he’d been asked by Trump to lead a commission on “vaccine safety,” we jumped in with authoritative stories on the science of vaccines, the president’s power to set vaccine policy — and a deeply reported opinion piece detailing Kennedy’s history of distorting the research in this field.


When Trump slammed drug companies for “getting away with murder,” we delivered not just the news, but the stories behind the story, including a piece from Singapore explaining how Trump has rattled an industry increasingly dependent on manufacturing ingredients overseas.

Our Trump in 30 Seconds weekday newsletter, which we introduced the Monday after the election, has quickly become one of the most popular of our 15 newsletters, with readers eager for our curated take on the latest news. You can sign up for it here.

If you find our journalism valuable, please support us by sampling our variety of newsletters and sharing our work on social media. Please also consider joining the many readers who have signed up for STAT Plus, our new subscription service that goes deep with exclusive, in-depth pharma and biotech coverage.

One final way you can help us: Reach out. We’re eager to speak to patients, doctors, nurses, and scientists about how you are affected by changes in the Trump administration. We protect the identity of our sources and treat submissions confidentially. Information on contacting individual reporters is here; use this page to send general correspondence.

Thank you for your support.

Rick Berke